Craig C. Hopkinson - 23 Feb 2024 Form 4 Insider Report for Alkermes plc. (ALKS)

Role
EVP R&D, Chief Medical Officer
Signature
/s/ Jeffrey Geary, attorney-in-fact for Craig C. Hopkinson
Issuer symbol
ALKS
Transactions as of
23 Feb 2024
Net transactions value
-$100,952
Form type
4
Filing time
27 Feb 2024, 16:03:26 UTC
Previous filing
23 Feb 2024
Next filing
06 Nov 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ALKS Ordinary Shares Options Exercise +7,689 +7.3% 113,123 23 Feb 2024 Direct F1
transaction ALKS Ordinary Shares Tax liability $100,952 -3,414 -3% $29.57 109,709 23 Feb 2024 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ALKS Restricted Stock Unit Award Options Exercise -7,689 -25% 23,068 23 Feb 2024 Ordinary Shares 7,689 Direct F1, F2
transaction ALKS Employee Stock Option (Right to Buy) Award $0 +111,186 $0.000000 111,186 26 Feb 2024 Ordinary Shares 111,186 $30.04 Direct F3
transaction ALKS Restricted Stock Unit Award Award $0 +27,464 $0.000000 27,464 26 Feb 2024 Ordinary Shares 27,464 Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit represents a contingent right to receive one ordinary share.
F2 Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 2/23/2024.
F3 Shares underlying the stock option vest and become exercisable in four equal annual installments commencing on 2/26/2025.
F4 Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 2/26/2025.